Non-Insulin Dependent Diabetes Mellitus (NIDDM) and Angiotensin Converting Enzyme 2 (ACE2): Diabetic Patients Treated With Antihypertensive Drugs
Recruitment status was Not yet recruiting
This feasibility study is designed to examine modulation of the relative activities of ACE and ACE2 in diabetic patients following treatment with the angiotensin type 1 receptor (AT1R) antagonist, Candesartan.
This study will provide a closer insight to the possible involvement of the renin-angiotensin system (RAS)-related enzymatic components in development or attenuation of vascular pathogenesis.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Educational/Counseling/Training
|Official Title:||ACE/ACE2 Ratio in Diabetic Patients Treated With Antihypertensive Drugs|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00192803
|Contact: Shlomo Keidar, MDfirstname.lastname@example.org|
|Internal Ward "A", Rambam Medical Center||Not yet recruiting|
|Contact: Ayelet Raz, MD 972-4-8543072|
|Sub-Investigator: Ayelet Raz, MD|
|Principal Investigator:||Shlomo Keidar, MD||Rambam Health Care Campus|